{
  "id": "5884fe4ce56acf5176000010",
  "type": "list",
  "question": "SPAG5 was implicated in which cancers?",
  "ideal_answer": "SPAG5 was implicated in prostate cancer, lung cancer and cervical cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24853425",
    "http://www.ncbi.nlm.nih.gov/pubmed/21412013",
    "http://www.ncbi.nlm.nih.gov/pubmed/27312051",
    "http://www.ncbi.nlm.nih.gov/pubmed/27037000",
    "http://www.ncbi.nlm.nih.gov/pubmed/24194916"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: We conducted multiple microarray datasets analyses from clinical and xenograft tumor tissues to search for disease progression-driving oncogenes in prostate cancer (PCa). Sperm-associated antigen 5 (SPAG5) attracted our attention. SPAG5 was recently identified as an oncogene participating in lung cancer and cervical cancer progression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27037000",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: Our results collectively showed a progression-driving role of SPAG5 in PCa which can be regulated by miR-539, suggesting that miR-539/SPAG5 can serve as a potential therapeutic target for PCa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27037000",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: We identified that SPAG5 expression was gradually increased in PCa progression and its level was significantly associated with lymph node metastasis, clinical stage, Gleason score, and biochemical recurrence. Our results indicated that SPAG5 knockdown can drastically inhibit PCa cell proliferation, migration, and invasion in vitro and supress tumor growth and metastasis in vivo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27037000",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "miR-539 inhibits prostate cancer progression by directly targeting SPAG5.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27037000",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Copy number aberration leading to SPAG5 gain or amplification and high SPAG5 transcript and SPAG5 protein concentrations were associated with shorter overall breast cancer-specific survival (METABRIC cohort [copy number aberration]: hazard ratio [HR]1\u00b750, 95% CI 1\u00b718-1\u00b792, p=0\u00b700010; METABRIC cohort [transcript]: 1\u00b768, 1\u00b740-2\u00b701, p<0\u00b70001; and Nottingham-HES-breast cancer cohort [protein]: 1\u00b768, 1\u00b732-2\u00b712, p<0\u00b70001). In multivariable analysis, high SPAG5 transcript and SPAG5 protein expression were associated with reduced breast cancer-specific survival at 10 years compared with lower concentrations (Uppsala: HR 1\u00b762, 95% CI 1\u00b703-2\u00b753, p=0\u00b7036; METABRIC: 1\u00b727, 1\u00b702-1\u00b758, p=0\u00b7034; untreated lymph node-negative cohort: 2\u00b734, 1\u00b724-4\u00b742, p=0\u00b70090; and Nottingham-HES: 1\u00b773, 1\u00b723-2\u00b746, p=0\u00b70020). In patients with oestrogen receptor-negative breast cancer with high SPAG5 protein expression, anthracycline-based adjuvant chemotherapy increased breast cancer-specific survival overall compared with that for patients who did not receive chemotherapy (Nottingham-oestrogen receptor-negative-ACT cohort: HR 0\u00b737, 95% CI 0\u00b720-0\u00b760, p=0\u00b70010). Multivariable analysis showed high SPAG5 transcript concentrations to be independently associated with longer distant relapse-free survival after receiving taxane plus anthracycline neoadjuvant chemotherapy (MD Anderson-NeoACT: HR 0\u00b768, 95% CI 0\u00b748-0\u00b797, p=0\u00b7031). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: SPAG5 is a novel amplified gene on Ch17q11.2 in breast cancer. The transcript and protein products of SPAG5 are independent prognostic and predictive biomarkers that might have clinical utility as biomarkers for combination cytotoxic chemotherapy sensitivity, especially in oestrogen receptor-negative breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853425",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Previously, we found that sperm-associated antigen 5 (SPAG5) was upregulated in pelvic lymph node metastasis-positive cervical cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853425",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In general, SPAG5 upregulation relates to poor prognosis in cervical cancer patients, and SPAG5 is a regulator of mTOR activity during taxol treatment in cervical cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853425",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: We identified novel genes whose expression was upregulated in NSCLC, including SPAG5, POLH, KIF23, and RAD54L, which are associated with mitotic spindle formation, DNA repair, chromosome segregation, and dsDNA break repair, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21412013",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Another module identified among male breast cancers, regulated by SPAG5, was closely associated with proliferation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In our study, SPAG5 expression in cervical cancer patients was detected using quantitative real-time polymerase chain reaction, western blotting, and immunohistochemistry; cervical cancer cell function with downregulated SPAG5 in vitro was explored using tetrazolium assay, flow cytometry, and colony formation and Transwell assays. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853425",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In patients with oestrogen receptor-negative breast cancer with high SPAG5 protein expression, anthracycline-based adjuvant chemotherapy increased breast cancer-specific survival overall compared with that for patients who did not receive chemotherapy (Nottingham-oestrogen receptor-negative-ACT cohort: HR 0\u00b737, 95% CI 0\u00b720-0\u00b760, p=0\u00b70010).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We investigated the clinicopathological relevance of SPAG5 gene copy number aberrations, mRNA transcript expression, and protein expression and analysed the associations of SPAG5 copy number aberrations, transcript expression, and protein expression with breast cancer-specific survival, disease-free survival, distant relapse-free survival, pathological complete response, and residual cancer burden in the Nottingham discovery cohort, Uppsala cohort, METABRIC cohort, a pooled untreated lymph node-negative cohort (n=684), a multicentre combined cohort (n=5439), the Nottingham historical early stage breast cancer cohort (Nottingham-HES; n=1650), N",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In multivariable analysis, high SPAG5 transcript and SPAG5 protein expression were associated with reduced breast cancer-specific survival at 10 years compared with lower concentrations (Uppsala: HR 1\u00b762, 95% CI 1\u00b703-2\u00b753, p=0\u00b7036; METABRIC: 1\u00b727, 1\u00b702-1\u00b758, p=0\u00b7034; untreated lymph node-negative cohort: 2\u00b734, 1\u00b724-4\u00b742, p=0\u00b70090; and Nottingham-HES: 1\u00b773, 1\u00b723-2\u00b746, p=0\u00b70020).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "THY1 may thus be a promising novel prognostic marker for male breast cancer. Another module identified among male breast cancers, regulated by SPAG5, was closely associated with proliferation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, men with THY1 positive breast cancers had significantly inferior survival. THY1 may thus be a promising novel prognostic marker for male breast cancer. Another module identified among male breast cancers, regulated by SPAG5, was closely associated with proliferation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SPAG5 was recently identified as an oncogene participating in lung cancer and cervical cancer progression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27037000",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SPAG5 is a novel amplified gene on Ch17q11.2 in breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Copy number aberration leading to SPAG5 gain or amplification and high SPAG5 transcript and SPAG5 protein concentrations were associated with shorter overall breast cancer-specific survival (METABRIC cohort [copy number aberration]: hazard ratio [HR] 1\u00b750, 95% CI 1\u00b718-1\u00b792, p=0\u00b700010; METABRIC cohort [transcript]: 1\u00b768, 1\u00b740-2\u00b701, p<0\u00b70001; and Nottingham-HES-breast cancer cohort [protein]: 1\u00b768, 1\u00b732-2\u00b712, p<0\u00b70001).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.uniprot.org/uniprot/SPAG5_HUMAN",
    "http://www.uniprot.org/uniprot/SPAG5_MOUSE"
  ],
  "exact_answer": "prostate cancer, lung cancer, cervical cancer, breast cancer"
}